吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, May 24 2019

Full Issue

New GOP Lawmakers' Silence After Campaigning On Drug Pricing Reveals Difficult Reality For Republicans

Reps. Dan Crenshaw (R-Texas) and Pete Stauber (R-Minn.) both talked on the campaign trail about giving Medicare negotiating powers as a way to curb high drug prices. Now, in Congress, they appear to have backpedaled their positions. Meanwhile, the spat between President Donald Trump and House Speaker Nancy Pelosi jeopardizes a potential deal on drug pricing. And Colorado caps the costs of insulin.

Both Reps. Dan Crenshaw of Texas and Pete Stauber of Minnesota have retreated from their campaign pledges on the issue 鈥 a sign, experts said, of both the political appeal of pledging to lower drug prices and the trepidation that comes with crossing the party line on a divisive issue. The political liability that comes with quickly abandoning a campaign-trail promise, too, could be substantial. (Facher, 5/24)

President Trump's new vow to cut off work with Democrats is threatening recent progress in bipartisan talks to lower drug prices. Staffers for the White House and Speaker Nancy Pelosi's (D-Calif.) office have been in discussions for months about potential legislation to lower the cost of prescription drugs, and sources say the White House has expressed openness to some form of Medicare negotiating drug prices, a major Democratic goal that Trump supported during the 2016 campaign before backing off. (Sullivan, 5/24)

Diabetics in Colorado who use insulin to control their blood sugar levels won鈥檛 pay more than $100 per month for the drug starting in January thanks to a bill signed into law by Gov. Jared Polis on Wednesday. 鈥淭oday, we will declare that the days of insulin price gouging are over in Colorado,鈥 Polis said in his office as he signed the bill, according to CBS Denver. Insulin has been around for nearly a century, but the price that patients with Type 1 and Type 2 diabetes pay for the drug has doubled since 2012, according to the Healthcare Cost Institute. The cost of insulin can creep up toward $1,000 for those whose health care coverage requires significant cost-sharing. (Staver, 5/23)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, August 7
  • Thursday, August 6
  • Wednesday, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF